Back

Comparison of Lp(a) assessment in patients with atherosclerotic cardiovascular disease between office-based cardiologists and general practitioners

1 September 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Lp(a) and apoproteins as risk factors Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Oliver Weingaertner

University hospital Jena, Jena (Germany)

7 More presentations in this session

Presentation thumbnail
Lp(a) testing and LDL-C levels among australian ASCVD patients in 2022: a cross-sectional study from the advara heartcare network (PREVAIL)
Doctor R. SANTANI (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Does the LPA genotype have a role in coronary artery disease risk beyond Lp(a) values?
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Causal associations of insulin and Lp(a) levels: a Mendelian randomization study
Associate Professor T. Osadnik (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
A retrospective analysis of patients with very HIGH level of LDL-C and the predictors of mortality (HIGH-LDL-PM Registry)
Associate Professor U. Sinan (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
The prevalence, patients characteristics and risk factors of hyper-Lp(a)-emia in the Polish population. The first results from the PMMHRI-Lp(a) Registry
Professor M. Banach (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Lp(a) and apoproteins as risk factors

The Event

Event poster

ESC Congress 2024

1 September 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
The differences in lipid lowering therapies and the LDL-C goal attainment in patients with ASCVD documented by cardiologists and general practitioners in Germany.
thumbnail
Congress Presentation
Physician perspectives on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study
thumbnail
Congress Presentation
Lp(a) testing and cardiovascular risk management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources